Given that this pathway is mutated in the majority of GBM and that the hyper-activated AKT helps glioma cells grow uncontrollably, evade apoptosis, and enhance tumor invasion, targeting this pathway has been an attractive therapeutic strategy for glioma (McDowell et al., 2011; Zhang et al., 2021). This evidence concerns the gene AKT1 and glioblastoma.